Navigation Links
Top Biopharma Company Adopts BioFortis' Translational Research Software for Centralized Management and Mining of Clinical Biomarker Data
Date:9/10/2008

COLUMBIA, Md., Sept. 10 /PRNewswire/ -- A top 5 bio-pharmaceutical company has licensed BioFortis' Labmatrix(TM) software for use enterprise-wide, across multiple therapeutic areas within its global Translational Medicine organization, BioFortis officials announced today. This large biopharmaceutical company decided to adopt the Labmatrix technology after an extensive review process that included a pilot by end users and the research informatics division. The company expects full implementation of Labmatrix to have a rapid and profound effect on the productivity of its Translational Medicine efforts.

"Labmatrix is the only data management and exploration application on the market that is built from the ground up to support translational medicine and biomarker discovery," said Jian Wang, BioFortis President and CEO. "There is a growing need in the biotechnology and pharmaceutical industry for robust informatics systems in the translational medicine space. This agreement demonstrates BioFortis' leadership position in fulfilling such needs," Dr. Wang concluded.

Labmatrix, an enterprise translational research information management software product, will be used to support Translational Medicine initiatives associated with research programs, clinical trials, and longitudinal clinical studies conducted with external collaborators.

About BioFortis

BioFortis is a privately-held company focused on providing biomedical research software and services to the life sciences sector, including government and academic research institutes and the biopharmaceutical industry. BioFortis' flagship product Labmatrix(TM) supports translational medicine initiatives with applications in clinical research, biobanking and biomarker discovery. Labmatrix enables transparent data management, integration, collaboration and compliance to privacy regulations.


'/>"/>
SOURCE BioFortis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Therapure Biopharma Inc. opens for business with first client contracts
2. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
3. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
4. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
5. Ondine Biopharma Announces Second Quarter 2008 Financial Results
6. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
8. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
9. ARCA biopharma Appoints James Carr as Vice President of Marketing
10. TriCipher is First to Transfer Smart Card Level Security to Federally Approved SAFE-BioPharma(TM) Roaming Credentials
11. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... Research and Markets has announced the addition of the ... 2021" report to their offering. ... The biosimilars market is expected to reach ... at a CAGR of 26.3%. The global biosimilars ... application. Factors such as rising incidence of various diseases, increasing demand ...
(Date:1/12/2017)... ... January 12, 2017 , ... MEXICO’S ... Technologies, Inc., announces the successful outcome of the first lumbar fusion procedure ... (Vertebral Technologies, Inc.) has partnered with Mexico-based medical product company BioMedical Technologies ...
(Date:1/12/2017)... 2017 The Energy and Resources ... for producing mycorrhizae. The Centre for Mycorrhizal Research at ... mycorrhizae and developed a technology that eventually produces mycorrhizae ... ... The TERI facility has a production capacity of ...
(Date:1/11/2017)... (PRWEB) , ... January 11, 2017 , ... ... journal Clinical Cancer Research show early promise of the investigational anti-cancer agent tucatinib ... a median 5 previous treatment regimens. Twenty-seven percent of these heavily pretreated patients ...
Breaking Biology Technology:
(Date:12/16/2016)... MIAMI , Dec. 16, 2016   ... intuitive Identity management products and solutions and a ... announced today that it is offering seamless, integrated ... Edam security entrance products. The solutions provide IdentyTech,s ... to secure their facilities from crime and theft. ...
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
(Date:12/15/2016)... 14, 2016 "Increase in mobile transactions is ... mobile biometrics market is expected to grow from USD ... 2022, at a CAGR of 29.3% between 2016 and ... the growing demand for smart devices, government initiatives, and ... "Software component is expected to grow at a high ...
Breaking Biology News(10 mins):